Anti-Mouse CD80

NS0-Derived Recombinant Mouse B7-1 Extracellular Domain (Accession # Q00609)

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: This antibody is useful for neutralization of Mouse B7-1 bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Mouse B7-1 (at 0.10 ng/ml) is 0.001 – 0.003 µg/ml.

Goat Anti-Mouse B7-1 recognizes Mouse B7-1. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

CD80 is a highly glycosylated 60 kD protein that is part of the Ig superfamily and is significantly involved in immune cell activation in response to pathogens. CD80 is closely related to, and works in tandem with CD86 (B7-2) to prime T- cells. CD80 binds to CTLA-4 to deliver an inhibitory signal to T cells. The ligation of CD28 on T cells with CD80 and CD86 on APCs co-stimulates T cells resulting in enhanced cell activation, proliferation, and cytokine production. It is thought that CD80 interacts with a ligand on Natural Killer cells, activating the Natural Killer cell-mediated cell death of the CD80 carrier. The activation of Natural Killer cell-mediated death via CD80 interactions has potential as a possible cancer immunotherapy through the induction of CD80 expression on tumor cells.